Awakn Life Sciences
Financials
Estimates*
CAD | 2022 | 2023 | 2024 |
---|---|---|---|
Revenues | <1m | 1.5m | <1m |
% growth | - | 534 % | (66 %) |
EBITDA | (9.6m) | (8.6m) | - |
% EBITDA margin | (4068 %) | (574 %) | - |
Profit | (15.9m) | (9.1m) | - |
% profit margin | (6756 %) | (611 %) | - |
R&D budget | 3.3m | 1.6m | - |
R&D % of revenue | 1402 % | 105 % | - |
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | $8.0m Valuation: $56.0m | IPO | |
* | N/A | $3.3m | Private Placement VC |
* | N/A | Grant | |
* | CAD775k | Post IPO Debt | |
* | N/A | CAD1.1m | Private Placement VC |
* | N/A | CAD2.7m | Post IPO Equity |
* | N/A | $131k | Private Placement VC |
* | N/A | $197k | Private Placement VC |
* | N/A | N/A | Private Placement VC |
Total Funding | $4.4m |
Related Content
Recent News about Awakn Life Sciences
EditAwakn Life Sciences is a biotechnology company dedicated to providing breakthrough therapeutics to addiction sufferers. They are researching, developing, and commercializing drugs and therapies used in combination to treat addiction, with a near-term focus on Alcohol Use Disorder. This approach has the potential to be more effective than any addiction treatment currently available.
Awakn is different from other businesses in the same industry by utilizing a unique evidence-based approach. Their drugs are designed to target the underlying causes of addiction, rather than just the symptoms. This approach has the potential to be more effective than any addiction treatment currently available, and Awakn is working to become the market leader in effective addiction treatment.
The company has a deep pipeline with proven efficacy, and a highly experienced team. There is a significant addressable market and a vast global need that is failed by current approaches. Awakn is working to meet this need and make a profit by commercializing their R&D pipeline across multiple channels.